Citations

Mayo Clinic

Showing 10 of 108602 citations.

External Validation of a Tube Thoracostomy Complication Classification System
Sritharen, Yoginee, Haddad, Nadeem N. , Kong, Victor , Clarke, Damian , Zielinski, Martin D. , Aho, Johnathon M. , Hernandez, Matthew C.

World Journal of Surgery | September 20, 2017 | Volume: 42 | Issue: 3 | Pages: 736-741

10.1007/s00268-017-4260-8 | PMID 28932968 Get It

AbstractBackgroundTube thoracostomy (TT) is a commonly performed procedure which is associated with significant complication rates. Currently, there is no validated taxonomy to classify and compare TT complications across different populations. This study aims to validate such TT complication taxonomy in a cohort of South African trauma patients.MethodsPost hoc analysis of a prospectively collected trauma database from Pietermaritzburg Metropolitan Trauma Service (PMTS) in South Africa was performed for the period January 2010 to December 2013. Baseline demographics, mechanism of injury and complications were collected and categorized according to published classification protocols. All patients requiring bedside TT were included in the study. Patients who necessitated operatively placed or image‐guided TT insertion were excluded. Summary and univariate analyses were performed.ResultsA total of 1010 patients underwent TT. The mean age was (±SD) of 26 ± 8 years. Unilateral TTs were inserted in n = 966 (96%) and bilateral in n = 44 (4%). Complications developed in 162 (16%) patients. Penetrating injury was associated with lower complication rate (11%) than blunt injury (26%), p = 0.0001. Higher complication rate was seen in TT placed by interns (17%) compared to TT placed by residents (7%), p = 0.0001. Complications were classified as: insertional (38%), positional (44%), removal (9%), infective/immunologic (9%), and instructional, educational or equipment related (0%).ConclusionsDespite being developed in the USA, this classification system is robust and was able to comprehensively assign and categorize all the complications of TT in this South African trauma cohort. A universal standardized definition and classification system permits equitable comparisons of complication rates. The use of this classification taxonomy may help develop strategies to improve TT placement techniques and reduce the complications associated with the procedure.Level of evidenceV.Study typeSingle Institution Retrospective review.
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Kiladjian, Jean‐Jacques , Catalano, John, Devos, Timothy , Egyed, Miklós , Hellmann, Andrzei, McLornan, Donal P. , Winton, Elliott F., Dubowy, Ronald L., Maltzman, Julia D., Cervantes, Francisco , Catalano, John V, McLornan, Donal, Shimoda, Kazuya , Gotlib, Jason , Kiladjian, Jean-Jacques , McLornan, Donal , Mesa, Ruben A. , Deng, Wei

Journal of Clinical Oncology | September 20, 2017 | Volume: 35 | Issue: 34 | Pages: 3844-3850

10.1200/jco.2017.73.4418 | PMID 28930494 Get It

Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive open-label momelotinib. The primary end point was a ≥ 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom response and effects on RBC transfusion requirements. Results A ≥ 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A ≥ 50% reduction in the total symptom score was observed in 28.4% and 42.2% of patients who received momelotinib and ruxolitinib, respectively, indicating that noninferiority was not met ( P = .98). Transfusion rate, transfusion independence, and transfusion dependence were improved with momelotinib (all with nominal P ≤ .019). The most common grade ≥ 3 hematologic abnormalities in either group were thrombocytopenia and anemia. Grade ≥ 3 infections occurred in 7% of patients who received momelotinib and 3% of patients who received ruxolitinib. Treatment-emergent peripheral neuropathy occurred in 10% of patients who received momelotinib (all grade ≤ 2) and 5% of patients who received ruxolitinib (all grade ≤ 3). Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response. Momelotinib treatment was associated with a reduced transfusion requirement.
Immobilization of vitronectin‐binding heparan sulfates onto surfaces to support human pluripotent stem cells
Yap, Lynn , Murali, Sadasivam, Bhakta, Gajadhar, Chen, Allen Kuan‐Liang, Sim, Lyn Chiin, Lim, Yu Ming , Goh, James Cho‐Hong , Oh, Steve , Choo, Andre , Wijnen, André J. van , Robinson, David E., Whittle, Jason D. , Short, Robert D. , Nurcombe, Victor , Cool, Simon M. , van Wijnen, Andre J , Titmarsh, Drew M. , Bardor, Muriel , Birch, William R.

Journal of Biomedical Materials Research Part B: Applied Biomaterials | September 20, 2017 | Volume: 106 | Issue: 5 | Pages: 1887-1896

10.1002/jbm.b.33999 | PMID 28941021 Get It

AbstractFunctionalizing medical devices with polypeptides to enhance their performance has become important for improved clinical success. The extracellular matrix (ECM) adhesion protein vitronectin (VN) is an effective coating, although the chemistry used to attach VN often reduces its bioactivity. In vivo, VN binds the ECM in a sequence‐dependent manner with heparan sulfate (HS) glycosaminoglycans. We reasoned therefore that sequence‐based affinity chromatography could be used to isolate a VN‐binding HS fraction (HS9) for use as a coating material to capture VN onto implant surfaces. Binding avidity and specificity of HS9 were confirmed by enzyme‐linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR)‐based assays. Plasma polymerization of allylamine (AA) to tissue culture‐treated polystyrene (TCPS) was then used to capture and present HS9 as determined by radiolabeling and ELISA. HS9‐coated TCPS avidly bound VN, and this layered surface supported the robust attachment, expansion, and maintenance of human pluripotent stem cells. Compositional analysis demonstrated that 6‐O‐ and N‐sulfation, as well as lengths greater than three disaccharide units (dp6) are critical for VN binding to HS‐coated surfaces. Importantly, HS9 coating reduced the threshold concentration of VN required to create an optimally bioactive surface for pluripotent stem cells. We conclude that affinity‐purified heparan sugars are able to coat materials to efficiently bind adhesive factors for biomedical applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1887–1896, 2018.
OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
Chiang, Chia‐Chun , Starling, Amaal J. , Chiang, Chia-Chun

Therapeutic Advances in Neurological Disorders | September 20, 2017 | Volume: 10 | Issue: 12 | Pages: 397-406

10.1177/1756285617731521 | PMID 29204191 Get It

Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. Since then, numerous studies have been performed investigating the short-term and long-term benefits, risks and complications of the use of onabotulinumtoxinA injections for the treatment of chronic migraine. The purpose of this narrative review is to describe the currently available clinical evidence for the use of onabotulinumtoxinA injections for treating patients with chronic migraine.
Faculty Opinions recommendation of Cutting edge: dual tcrα expression poses an autoimmune hazard by limiting regulatory T cell generation.
Shapiro, Virginia Smith

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727650337.793536656 Get It

Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single‐centre study, systematic review and meta‐analysis
Ye, Lei , Wang, Weixi , Wang, Weixi, Ospina, Naykky Singh , Jiang, Lei , Christakis, Ioannis , Lu, Jieli , Zhou, Yulin , Cao, Yanan , Wang, Shu , Ning, Guang , Wang, Weiqing, Wang, Weiqing, Ospina, Naykky Singh , Wang, Weixi, Zhu, Wei Ping , Perrier, Nancy D. , Young, William F. , Wang, Weiqing, Wang, Weiqing, Singh Ospina, Naykky

Clinical Endocrinology | September 20, 2017 | Volume: 87 | Issue: 6 | Pages: 706-716

10.1111/cen.13480 | PMID 28940393 Get It

SummaryObjectiveThymic neuroendocrine tumour (TH‐NET) accounts for almost 20% of multiple endocrine neoplasia type 1 (MEN1)‐associated mortality. Identifying risk factors for the development of these rare tumours and prognostic factors for clinical outcomes will be helpful in clinical practice.Design and PatientsWe performed a retrospective analysis of patients treated for TH‐NET associated with MEN1 in a single institution and meta‐analysis of literature reports. We used a fixed effect model to pool results across studies to evaluate the prevalence, clinical features and prognosis.ResultsTH‐NET was detected in 9 (7.4%) of 121 patients with MEN1 seen in our institution, and 5 (55.6%) were women. Seven additional studies were identified through a systematic review of the literature. The pool estimate of TH‐NET prevalence was 3.7% (n = 99) in MEN1 (n = 2710), sex ratio was 79:20 (male vs female), and the median age at diagnosis was 43.0 years (range, 16.0‐72.0 years). Forty‐three patients died with a median survival time of 8.4 years. Older age at diagnosis (HR = 1.4, 95% CI = 1.0‐1.8, P = .03), maximum tumour diameter (HR = 1.5, 95% CI = 1.0‐2.3, P = .04) and presence of metastasis (HR = 1.6, 95% CI = 1.0‐2.5, P = .04) were associated with worse outcome. A male predominance (91.9% vs 59.5%, P < .001) and history of smoking (59.0% vs 23.5%, P = .015) were more common in American/European series compared to Asian reports.ConclusionTH‐NET is a rare but fatal component of MEN1. Earlier detection of TH‐NET in patients with MEN1 may be recommended which should theoretically result in better outcomes. Different genetic backgrounds (race) appear to result in clinical difference.
Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
Volta, Mattia , Beccano-Kelly, Dayne , Paschall, Sarah A. , Cataldi, Stefano , MacIsaac, Sarah E, Kuhlmann, Naila , Kadgien, Chelsie , Tatarnikov, Igor , Fox, Jesse D. , Khinda, Jaskaran, Mitchell, Emma , Bergeron, Sabrina , Melrose, Heather L. , Farrer, Matthew J. , Milnerwood, Austen J. , Beccano-Kelly, Dayne A , Melrose, Heather

eLife | September 20, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.28377 | PMID 28930069 Get It

LRRK2 mutations produce end-stage Parkinson’s disease (PD) with reduced nigrostriatal dopamine, whereas, asymptomatic carriers have increased dopamine turnover and altered brain connectivity. LRRK2 pathophysiology remains unclear, but reduced dopamine and mitochondrial abnormalities occur in aged G2019S mutant knock-in (GKI) mice. Conversely, cultured GKI neurons exhibit increased synaptic transmission. We assessed behavior and synaptic glutamate and dopamine function across a range of ages. Young GKI mice exhibit more vertical exploration, elevated glutamate and dopamine transmission, and aberrant D2-receptor responses. These phenomena decline with age, but are stable in littermates. In young GKI mice, dopamine transients are slower, independent of dopamine transporter (DAT), increasing the lifetime of extracellular dopamine. Slowing of dopamine transients is observed with age in littermates, suggesting premature ageing of dopamine synapses in GKI mice. Thus, GKI mice exhibit early, but declining, synaptic and behavioral phenotypes, making them amenable to investigation of early pathophysiological, and later parkinsonian-like, alterations. This model will prove valuable in efforts to develop neuroprotection for PD.
Circulating CD34+ Cell Count is Associated with Extent of Subclinical Atherosclerosis in Asymptomatic Amish Men, Independent of 10-Year Framingham Risk
Bielak, Lawrence F. , Horenstein, Richard B., Sheedy, Patrick F. , Rumberger, John A. , Tanner, Keith, Peyser, Patricia A. , Ryan, Kathleen A. , Post, Wendy S. , Mitchell, Braxton D. , Shuldiner, Alan R.

Clinical medicine. Cardiology | September 20, 2017 | Volume: 3 | Issue: No issue available | Pages: CMC.S2111

10.4137/cmc.s2111 | PMID 20407620 Get It

Background Bone-marrow derived progenitor cells (PCs) may play a role in maintaining vascular health by actively repairing damaged endothelium. The purpose of this study in asymptomatic Old Order Amish men (n = 90) without hypertension or diabetes was to determine if PC count, as determined by CD34+ cell count in peripheral blood, was associated with 10-year risk of cardiovascular disease (CVD) and measures of subclinical atherosclerosis. Methods and Results CD34+ cell count by fluorescence-activated cell sorting, coronary artery calcification (CAC) by electron beam computed tomography, and CVD risk factors were obtained. Carotid intimal-medial thickness (CIMT) also was obtained in a subset of 57 men. After adjusting for 10-year CVD risk, CD34+ cell count was significantly associated with CAC quantity ( p =0.03) and CIMT ( p < 0.0001). A 1-unit increase in natural-log transformed CD34+ cell count was associated with an estimated 55.2% decrease (95% CI: −77.8% to −9.3%) in CAC quantity and an estimated 14.3% decrease (95% CI: −20.1% to −8.1%) in CIMT. Conclusions Increased CD34+ cell count was associated with a decrease in extent of subclinical atherosclerosis in multiple arterial beds, independent of 10-year CVD risk. Further investigations of associations of CD34+ cell count with subclinical atherosclerosis in asymptomatic individuals could provide mechanistic insights into the atherosclerotic process.
Exercise-Echocardiography-Derived Pulmonary Artery Pressure Slope in Borderline and Mild to Moderate Pulmonary Arterial Hypertension
Ammash, Naser M., McGoon, Michael D., Shub, Clarence, Seward, James B., Oh, Jae K. , Krowka, Michael J. , Moon, Brenda S., Bailey, Kent R. , Wood, Christina M., Tajik, A. Jamil , Pellikka, Patricia A.

Clinical medicine. Cardiology | September 20, 2017 | Volume: 2 | Issue: No issue available | Pages: CMC.S740

10.4137/cmc.s740 Get It

Measurement with a wink
Kunneman, Marleen , Montori, Víctor M. , Shah, Nilay D. , Montori, Victor M

BMJ Quality & Safety | September 20, 2017 | Volume: 26 | Issue: 10 | Pages: 849-851

10.1136/bmjqs-2017-006814 | PMID 28733369 Get It